A standard coronary CT angiogram (CCTA, ~$400 to $450 self-pay) uses IV contrast dye to see both hardened calcium and the soft, non-calcified plaque that a calcium score of zero misses. Standard CCTA is the only heart CT strategy proven in randomized trials (SCOT-HEART 10-year follow-up) to reduce heart attacks by guiding earlier preventive therapy. Cleerly is an optional $1,500 AI software overlay on that same CCTA file that measures plaque volume in cubic millimeters (mm³). While Cleerly has strong observational risk-prediction data, zero completed randomized trials show that AI plaque staging improves survival or prevents more heart attacks than a standard CAD-RADS 2.0 CCTA paired with driving ApoB below 60 mg/dL.
TL;DR - The Plain-Language Summary
- What a CCTA sees that a Calcium Score misses: A $100 to $150 coronary calcium score (CAC) only sees old, calcified bone-like scars. Across 37,808 asymptomatic adults with a calcium score of zero (CAC = 0), 10% to 16% still carry soft, non-calcified plaque on a contrast CCTA (24.2% when Lp(a) is high, and 42% to 58% of plaques in adults under 40).
- The $450 Standard CCTA vs. the $2,000 Cleerly AI Add-On: Both use the same CT scanner, the same IV contrast trip, and the same radiation dose (0.5 to 2.5 mSv on modern dual-source scanners). A standard radiologist read (CAD-RADS 2.0,
$400 to $450) tells us whether soft plaque or high-risk plaque features exist today. Adding the Cleerly AI software layer ($1,800 to $2,200 total) outputs a plaque volume in cubic millimeters (mm³). - The clinical evidence gap: Standard CCTA is the only modality here proven in a 10-year randomized clinical trial (SCOT-HEART, n = 4,146) to cut heart attacks by 28% (HR 0.72) through earlier statin and lipid therapy. By contrast, both the 2025 American College of Cardiology (ACC) Scientific Statement and 2026 QCI Consensus note that zero completed randomized trials show AI plaque staging improves clinical outcomes over standard CAD-RADS 2.0 CCTA plus lipid lowering (the first randomized trial, TRANSFORM, is still enrolling).
- Your Monday-morning rule: If you want to know whether soft plaque is hiding behind a zero calcium score or borderline cholesterol today -> Then order the $400 to $450 standard-read CCTA first, and save the $1,500 Cleerly AI fee unless you plan to pay for a repeat scan in 2 to 3 years to track cubic-millimeter shrinkage.
Longevity clinics often present heart imaging as an all-or-nothing choice between a basic $100 calcium score and a $2,000+ Cleerly AI scan. Meanwhile, traditional primary care clinics rarely look at the coronary arteries at all until someone develops chest pain on a treadmill.
Both approaches leave patients with the wrong impression. If you want to see whether early, rupture-prone soft plaque has started building inside your heart arteries, you do not have to spend $2,000. The workhorse test that sees soft plaque is the standard coronary CT angiogram (CCTA), which costs roughly $400 to $450 self-pay at Philadelphia and South Jersey imaging centers. Cleerly (AI-QCT) is an optional post-processing software fee layered onto that same CT file after you leave the scanner.12

Why Does a Calcium Score of Zero (CAC = 0) Miss Soft Plaque in Younger Adults?
A calcium score of zero (CAC = 0) misses 10% to 16% of asymptomatic adults who carry soft, non-calcified plaque - including 58% of obstructive plaques under age 40, 34% in your 40s, and 24.2% of adults with high Lp(a) (>= 125 nmol/L).
When cholesterol-carrying ApoB particles enter the inner wall of a coronary artery, the plaque they form starts out soft, lipid-rich, and non-calcified. It takes years of healing and scarring for the body to lay down calcium inside that plaque. Because a non-contrast calcium score only detects dense calcium crystals, early soft plaque is invisible to it.34
Four landmark imaging studies quantify how often CAC = 0 misses active disease:
- Pooled asymptomatic prevalence (10% to 16.2%): Across a meta-analysis of 14 studies and 37,808 asymptomatic adults with CAC = 0, 10% carried non-calcified soft plaque (95% CI 6% to 13%), with men carrying more than triple the odds of women (OR 3.22).3 In the Swedish SCAPIS cohort (n = 25,182, ages 50 to 64), 5.5% of CAC = 0 adults had plaque on CCTA (7.3% of men, 4.3% of women, and 9.2% of intermediate-risk adults).5 In the U.S. Miami Heart Study (n = 2,359 asymptomatic adults aged 40 to 65), 16.2% of participants with CAC = 0 had coronary plaque, and 91% of those plaques (14.8% overall) were purely non-calcified soft plaque.6
- The under-55 age trap (Mortensen et al., JAMA Cardiology 2022 & NEJM 2026): Because younger arteries have not had decades to calcify, a zero score is least reliable under age 55. In 23,759 symptomatic patients (JAMA Cardiology), the share of obstructive coronary blockages (>= 50% narrowing) that had a CAC = 0 score was 58% under age 40, 34% at ages 40 to 49, 18% at ages 50 to 59, and only 5% at age 70 and older.7 In the 2026 New England Journal of Medicine population study (Bundgaard et al.), 41.8% of men and 48.4% of women aged 30 to 39 who had coronary plaque on CCTA had a calcium score of zero.8
- High Lp(a), high LDL-C / ApoB, and family history: In Miami Heart, statin-naive adults with CAC = 0 and high Lp(a) (>= 125 nmol/L) had a 24.2% prevalence of hidden plaque compared to 14.2% when Lp(a) was normal (p < 0.001), along with nearly quadruple the odds of carrying 2 or more high-risk plaque features (OR 3.94).9 Similarly, as LDL-C rose from < 70 mg/dL to >= 190 mg/dL in CAC = 0 adults, hidden plaque doubled from 13.2% to 28.2% in Miami Heart and from 11.4% to 22.8% in the Western Denmark Heart Registry (n = 23,777), where higher LDL-C drove a 39% jump in soft plaque odds per 1 mmol/L (38.7 mg/dL) in adults 45 and under (aOR 1.39, event aHR 1.37).1011
- Prognostic danger when soft plaque narrows the vessel or shows high-risk features: In the CONFIRM registry (n = 10,037), patients with CAC = 0 who had obstructive soft plaque (>= 50% narrowing) had a 5.7-fold higher risk of cardiac events (3.9% vs 0.8%, HR 5.7), and in the ICONIC acute coronary syndrome study, 23% of patients who suffered a heart attack or unstable angina had CAC = 0.1213 Across 13,977 patients (Nerlekar et al.), specific high-risk soft plaque features visible on a standard CCTA multiplied event risk: positive outward remodeling (HR 2.58), low-attenuation lipid-core plaque (< 30 HU, HR 2.95), napkin-ring sign (HR 5.06), and 2 or more high-risk features (HR 9.17).14
For that reason, the 2026 ACC/AHA Dyslipidemia Guideline states that a calcium score of zero (CAC = 0) should not be used to hold off on statin therapy in adults with a strong family history of premature heart disease (MESA HR 1.73), diabetes (30% plaque rate in Miami Heart and only a 3-year CAC = 0 warranty), current smoking (MESA HR 2.19), or familial hypercholesterolemia (LDL-C >= 190 mg/dL).1516
Does Cleerly AI Improve Heart Outcomes Over a Standard $450 CCTA?
No completed randomized trial shows that Cleerly AI plaque staging prevents more heart attacks than a standard radiologist-read CCTA (CAD-RADS 2.0) paired with intensive lipid lowering - while standard CCTA is proven over 10 years (SCOT-HEART) to cut heart attacks by 28%.
To spend your healthcare dollars wisely, it helps to separate two questions: 1) Does looking inside the arteries with a CCTA prevent heart attacks? and 2) Does paying an extra $1,500 for AI software on top of that CCTA improve outcomes further?
1. Standard CCTA has 10-year randomized trial proof (SCOT-HEART)
In the landmark SCOT-HEART randomized trial (n = 4,146 patients with stable chest pain), adding a standard-read CCTA to usual care lowered coronary death or nonfatal heart attack by 41% at 5 years (2.3% vs 3.9%, HR 0.59, p = 0.004).17 In the 10-year follow-up published in The Lancet (2025), the protection held strong: coronary death or nonfatal heart attack remained 21% lower (6.6% vs 8.2%, HR 0.79, p = 0.044) and nonfatal heart attacks were 28% lower (HR 0.72, p = 0.017).18
How did SCOT-HEART prevent heart attacks? Rates of coronary stents and bypass surgery were identical between groups (HR 1.00).18 Seeing the non-calcified plaque on a standard CCTA prompted doctors and patients to start preventive statin and antiplatelet therapy early instead of waiting for a blockage to rupture. Similarly, in the 10.6-year follow-up of the PROMISE randomized trial (n = 10,003, JAMA Cardiology 2025), any plaque abnormality on CCTA predicted long-term mortality (adjusted HR 1.99 to 3.44) far more sensitively than mild or moderate stress-test abnormalities.19
2. What AI quantitative plaque overlays (Cleerly / AI-QCT) add - and where the evidence stops
Software platforms like Cleerly (AI-QCT) and HeartFlow Plaque run automated voxel-by-voxel segmentation on the raw CCTA file to calculate total plaque volume (TPV in mm³), percent atheroma volume (PAV), non-calcified plaque volume (NCPV), and low-attenuation necrotic-core volume (< 30 HU).12
Across observational registries and post-hoc trial re-reads, higher AI plaque volumes consistently track with higher event rates, though the incremental boost over a standard CAD-RADS 2.0 radiologist read is modest in most cohorts:
Fishtown Medicine
A 90-minute conversation with Dr. Ash. A written plan you can follow.
| Study / Cohort | Sample Size | AI Quantitative Plaque Finding (Verbatim) | Incremental Discrimination vs. Standard Read (Gist) |
|---|---|---|---|
| CONFIRM2 Registry (2026)20 | 1,916 | AI-quantified non-calcified plaque volume predicted death or MI in non-obstructive disease | Modest AUC gain over CAD-RADS 2.0 (0.81 vs 0.79; NRI 0.47) and over CAC (0.79 vs 0.70) |
| 10-Year Staging Cohort (Nurmohamed 2024)21 | 536 | Stage 3 non-calcified plaque (> 7.5% PAV) carried adjusted HR 4.37 for 10-year events | AUC improved from 0.78 (CAD-RADS 2.0) to 0.82 (p = 0.032; NRI 0.09) |
| ISCHEMIA Trial Post-Hoc (2024)22 | 3,711 | Total plaque volume (TPV) predicted CV death or MI (adjusted HR 1.56 per IQR, p = 0.001) | Small AUC change (0.65 vs 0.61) over clinical and anatomic variables |
| SCOT-HEART Deep-Learning & LAP Substudies2324 | 1,611 | Low-attenuation plaque burden > 4% carried HR 4.65 for MI (~7x in non-obstructive plaque); TPV >= 238.5 mm³ carried HR 5.36 | Proves soft lipid-core burden drives heart attacks independent of percent narrowing |
| ADVANCE Registry (HeartFlow 2024)25 | 4,430 | Total plaque volume > 564 mm³ carried adjusted HR 1.52 (p = 0.013) beyond stenosis + FFRct | Adds prognostic stratification in patients already undergoing functional flow modeling |
| CORE320 Multicenter Study (Negative)1 | 381 | Quantitative plaque features did not improve prediction over standard CAC (AUC 0.64 vs 0.65) | Shows AI volume does not outperform simpler scoring in every population |
Both the 2025 ACC Scientific Statement on Quantitative Coronary Plaque Analysis (Chandrashekhar et al.) and the 2026 QCI Study Group Consensus (Nature Reviews Cardiology) emphasize a central boundary: while AI plaque software changes physician prescribing in > 50% of clinic visits (CERTAIN and DECIDE registries), there is currently zero randomized trial evidence showing that AI-staged treatment prevents more heart attacks than a standard CAD-RADS 2.0 CCTA paired with aggressive ApoB lowering.2232627 The first randomized outcomes trial testing AI plaque staging (TRANSFORM, NCT06112418) is still enrolling.12
What Is the Cost and Radiation Ladder for Heart Scans in Philadelphia?
A $400 to $450 standard-read CCTA delivers 0.5 to 2.5 mSv on a modern dual-source scanner and answers whether you have soft plaque today, while the $1,800 to $2,200 Cleerly add-on adds 0 mSv of extra radiation and is reserved for serial mm³ tracking.
When you compare cardiac imaging options in Greater Philadelphia and South Jersey (such as our preferred independent 3T/dual-source centers like Princeton Radiology in Newtown), four steps rest on the ladder:
| Heart Imaging Option | Typical Self-Pay Cost | Typical vs. Best-Case Modern Radiation (mSv) | What It Sees (Evaluative Boundary) | When Fishtown Medicine Orders It |
|---|---|---|---|---|
| 1. Carotid + Abdominal Aortic Ultrasound | ~$100 (or insurance-covered) | 0 mSv (sound waves only) | Plaque in the neck or abdominal aorta; cannot see the coronary arteries | Fast, zero-radiation check to see if atherosclerosis has started in surface vessels |
| 2. Coronary Calcium Score (CAC) | $100 to $150 | 0.5 to 1.5 mSv (0.37 mSv with iterative reconstruction)28 | Hardened calcified scars only; misses 10% to 16% of soft plaque (58% under age 40) | First-line triage in lower-risk, non-smoking adults over 50 without high Lp(a) or family history |
| 3. Standard-Read CCTA (CAD-RADS 2.0) | $400 to $450 | 0.5 to 2.5 mSv on 3rd-gen dual-source CT (0.21 to 0.63 mSv high-pitch spiral when HR < 60 bpm)2930 | Soft non-calcified plaque, calcified plaque, high-risk plaque features, and stenosis; proven in SCOT-HEART RCT | Our default high-value choice when ApoB or Lp(a) is high, family history is strong, or we need a tie-breaker on starting a statin |
| 4. CCTA + Cleerly AI Overlay (AI-QCT) | $1,800 to $2,200 | Same as underlying CCTA (+0 mSv from AI) - avoid bundling an unneeded separate CAC scan that doubles dose2 | Outputs precise plaque volumes in mm³ (LD-NCP, non-calcified, calcified) for serial comparison | Reserved for patients who already know they want to pay for a repeat scan in 24 to 36 months to measure mm³ plaque regression |
Two radiation tips that cut your dose in half
- Choose a modern 3rd-generation dual-source CT scanner and prep your heart rate below 60 bpm: In the 2026 JAMA worldwide radiation study (Einstein et al.), median CCTA dose across random global centers was 5.6 to 7.4 mSv, with 72% of the variation coming down to center protocol instead of patient size.31 On a modern 3rd-generation dual-source scanner using high-pitch spiral mode (Flash mode when resting heart rate is < 60 bpm) and deep-learning image reconstruction (Benz et al.), total radiation drops by 43% down to 0.21 to 1.5 mSv - roughly equal to a standard calcium score or a few months of natural background radiation.293032
- Do not let an AI protocol tack on a redundant non-contrast CAC scan if you only need the CCTA: Because Cleerly and other AI software run directly on the contrast CCTA images, the AI analysis itself adds 0 mSv of radiation.2 However, some imaging bundles automatically perform both a non-contrast CAC scan and a contrast CCTA back-to-back, which adds 0.5 to 1.5 mSv of extra radiation you do not need if the decision rests on soft plaque.2
Who Should Avoid a CCTA (or Use a Different Test)?
- Severe kidney disease (eGFR < 30 mL/min) or severe iodine contrast allergy: Because CCTA requires intravenous iodine contrast dye, we use non-contrast calcium scoring, carotid ultrasound, or stress echocardiography instead.
- Asymptomatic adults under age 35 without genetic risk: Unless you have familial hypercholesterolemia (LDL-C >= 190 mg/dL), extreme Lp(a), or a parent who had a heart attack in their 30s or 40s, we drive prevention from your ApoB and Lp(a) blood panel instead of radiating the chest in your 20s or early 30s.
- Annual repeat scanners: Repeating a CCTA every 12 months adds unnecessary radiation and contrast exposure. Even in randomized plaque-regression trials (CAUGHT-CAD), meaningful differences in non-calcified plaque volume (5.6 vs 15.7 mm³ on atorvastatin 40 mg) are tracked over 24 to 36 months.233
Your Monday-Morning Heart Imaging Protocol (If -> Then Rules)
- If you are under 55, have high Lp(a) (>= 125 nmol/L), high ApoB, or a premature family history -> Then do not use a Calcium Score of 0 to talk yourself out of treatment. Under age 50, 34% to 58% of significant coronary plaques have CAC = 0, and the 2026 ACC/AHA guideline explicitly rules against deferring statins in high-risk family history, diabetes, smoking, or FH on the basis of zero calcium.715
- If you want to know whether soft plaque exists in your arteries today -> Then order a $400 to $450 standard-read CCTA (with CAD-RADS 2.0 grading) on a modern dual-source scanner. You get the only imaging test proven in randomized trials (SCOT-HEART) to cut heart attacks over 10 years, at one-fifth the price of an AI bundle.18
- If your CCTA shows any non-calcified soft plaque or high-risk plaque features -> Then drive ApoB below 60 mg/dL (or < 50 mg/dL if Lp(a) is high). Once plaque is visible inside the artery wall, the debate between lifestyle and medication is settled: we combine nutrition, exercise, and targeted lipid therapy (statins, ezetimibe, or PCSK9 inhibitors) to delipidate and stabilize the plaque.1833
- If you are booked for a CCTA -> Then prep your heart rate below 60 bpm the morning of the scan. Skip caffeine for 12 hours, fast for 4 hours, hold PDE5 inhibitors (sildenafil or tadalafil) for 48 hours, and take the prescribed morning oral beta-blocker (metoprolol) so the scanner can use its lowest-radiation (0.5 to 1.5 mSv), sharpest-image mode.2930
A note on cost: any discount we negotiate on labs and imaging passes straight through to you, with no markup. Our affordable labs and imaging guide covers how the billing works.
Scientific References
- Cramer SHM, Danad I, Knaapen P, Nurmohamed NS, Choi AD. Innovations in artificial intelligence-guided atherosclerosis cardiovascular imaging: from detection to prognosis. Curr Atheroscler Rep. 2026;28(1):15. DOI
- Saiani R, Ballantyne CM. Coronary computed tomography and artificial intelligence-based plaque analysis. Curr Atheroscler Rep. 2026;28(1):19. DOI
- Sama C, Abdelhaleem A, Velu D, et al. Non-calcified plaque in asymptomatic patients with zero coronary artery calcium score: a systematic review and meta-analysis. J Cardiovasc Comput Tomogr. 2023;17(6):405-414. PubMed
- Slipczuk L, Blankstein R, Bucciarelli-Ducci C, et al. State of the art: evaluation and medical management of nonobstructive coronary artery disease in patients with chest pain: a scientific statement from the American Heart Association. Circulation. 2025;151(8):e650-e672. DOI
- Bergstrom G, Persson M, Adiels M, et al. Prevalence of subclinical coronary artery atherosclerosis in the general population (SCAPIS). Circulation. 2021;144(12):916-929. PubMed
- Nasir K, Cainzos-Achirica M, Valero-Elizondo J, et al. Coronary atherosclerosis in an asymptomatic U.S. population: Miami Heart Study at Baptist Health South Florida. JACC Cardiovasc Imaging. 2022;15(9):1604-1618. PubMed
- Mortensen MB, Gaur S, Frimmer A, et al. Association of age with the diagnostic value of coronary artery calcium score for ruling out coronary stenosis in symptomatic patients. JAMA Cardiol. 2022;7(1):36-44. DOI
- Bundgaard H, Garcia-Lunar I, Kofoed KF, et al. Prevalence of silent atherosclerosis across adult life. N Engl J Med. 2026. DOI
- Mszar R, Cainzos-Achirica M, Valero-Elizondo J, et al. Lipoprotein(a) and coronary plaque in asymptomatic individuals: the Miami Heart Study at Baptist Health South Florida. Circ Cardiovasc Imaging. 2024;17(7):e016152. PubMed
- Hagan K, Mszar R, Cainzos-Achirica M, et al. Low-density lipoprotein-cholesterol and subclinical coronary atherosclerosis in a middle-aged asymptomatic U.S. population: the Miami Heart Study. Atherosclerosis. 2024;397:118562. PubMed
- Andersen MH, Jensen JM, Kanstrup H, et al. Low-density lipoprotein cholesterol and cardiovascular risk in the absence of calcifications on computed tomography: the Western Denmark Heart Registry. Eur Heart J. 2025;46(34):3312-3322. PubMed
- Villines TC, Hulten EA, Shaw LJ, et al. Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography: results from the CONFIRM registry. J Am Coll Cardiol. 2011;58(24):2533-2540. PubMed
- Jonas RA, Nurmohamed NS, Crabtree TR, et al. CTA-derived plaque characteristics and risk of acute coronary syndrome in patients with coronary artery calcium score of zero: insights from the ICONIC trial. AJR Am J Roentgenol. 2025;224(6):e2432110. PubMed
- Nerlekar N, Ha FJ, Cheshire C, et al. Computed tomographic coronary angiography-derived plaque characteristics predict major adverse cardiovascular events: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2018;11(1):e006973. PubMed
- Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia. Circulation. 2026. DOI
- Al Rifai M, Blaha MJ, Nambi V, et al. Determinants of incident atherosclerotic cardiovascular disease events among those with absent coronary artery calcium: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2022;145(4):259-267. PMC
- SCOT-HEART Investigators, Newby DE, Adamson PD, et al. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med. 2018;379(10):924-933. DOI
- Williams MC, Wereski R, Tuck C, et al. Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland. Lancet. 2025;405(10476):329-340. PubMed
- Douglas PS, Stebbins A, Foldyna B, et al. Survival after initial stress testing vs anatomic testing in suspected coronary artery disease: long-term follow-up of the PROMISE randomized clinical trial. JAMA Cardiol. 2025;10(10):1012-1021. DOI
- van Rosendael A, Nakanishi R, Bax JJ, et al. Prognostic value of AI-based quantitative coronary CTA vs human reader-based visual assessment: results from the CONFIRM2 registry. JACC Cardiovasc Imaging. 2026;19(2):188-200. PubMed
- Nurmohamed NS, Bom MJ, Jukema RA, et al. AI-guided quantitative plaque staging predicts long-term cardiovascular outcomes in patients at risk for atherosclerotic CVD. JACC Cardiovasc Imaging. 2024;17(3):269-280. PubMed
- Nurmohamed NS, Min JK, Anthopolos R, et al. Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial. Eur Heart J. 2024;45(36):3735-3747. PMC
- Schulze K, Stantien AM, Williams MC, et al. Coronary CT angiography evaluation with artificial intelligence for individualized medical treatment of atherosclerosis: a consensus statement from the QCI Study Group. Nat Rev Cardiol. 2026;23(2):112-128. DOI
- Williams MC, Kwiecinski J, Doris M, et al. Low-attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction: results from the multicenter SCOT-HEART trial. Circulation. 2020;141(18):1452-1462. PubMed
- Dundas J, Leipsic J, Fairbairn T, et al. Interaction of AI-enabled quantitative coronary plaque volumes on coronary CT angiography, FFRCT, and clinical outcomes: a retrospective analysis of the ADVANCE registry. Circ Cardiovasc Imaging. 2024;17(3):e016140. PubMed
- Nurmohamed NS, Cole JH, Budoff MJ, et al. Impact of atherosclerosis imaging-quantitative computed tomography on diagnostic certainty, downstream testing, coronary revascularization, and medical therapy: the CERTAIN study. Eur Heart J Cardiovasc Imaging. 2024;25(6):857-866. PubMed
- Rinehart S, Blankstein R, McCarthy CP, et al. Guiding preventive care strategies for patients with atherosclerotic plaque on coronary CTA: primary outcomes of the DECIDE registry. JACC Cardiovasc Imaging. 2026;19(4):412-424. PubMed
- Patel AA, Fine J, Naghavi M, Budoff MJ. Radiation exposure and coronary artery calcium scans in the Society for Heart Attack Prevention and Eradication cohort. Int J Cardiovasc Imaging. 2019;35(1):179-183. DOI
- Kosmala A, Petritsch B, Weng AM, Bley TA, Gassenmaier T. Radiation dose of coronary CT angiography with a third-generation dual-source CT in a true-world patient population. Eur Radiol. 2019;29(8):4341-4348. PubMed
- Stehli J, Fuchs TA, Bull S, et al. Accuracy of coronary CT angiography using a submillisievert fraction of radiation exposure: comparison with invasive coronary angiography. J Am Coll Cardiol. 2014;64(8):772-780. PubMed
- Einstein AJ, Williams MC, Weir-McCall JR, et al. Worldwide radiation dose in coronary artery disease diagnostic imaging. JAMA. 2026;335(11):980-992. DOI
- Benz DC, Ersozlu S, Mojon FLA, et al. Radiation dose reduction with deep-learning image reconstruction for coronary computed tomography angiography. Eur Radiol. 2022;32(4):2620-2628. PubMed
- Nerlekar N, Vasanthakumar SA, Whitmore K, et al. Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: a randomized clinical trial (CAUGHT-CAD). JAMA. 2025;333(12):1045-1054. DOI
Dr. Ash is a board-certified internal medicine physician at Fishtown Medicine in Philadelphia. He practices Medicine 3.0 preventive cardiology so your heart lasts as long as your ambition.
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.





